Successful Treatment of Small-Cell Lung Cancer With Irinotecan in a Hemodialysis Patient With End-Stage Renal Disease.
10.3904/kjim.2009.24.1.73
- Author:
Dong Min KIM
1
;
Hyun Lee KIM
;
Choon Hae CHUNG
;
Chi Young PARK
Author Information
1. Department of Internal Medicine, College of Medicine, Chosun University, Gwangju, Korea. pcy@chosun.ac.kr
- Publication Type:Case Report ; Research Support, Non-U.S. Gov't
- Keywords:
Small-cell lung cancer;
Hemodialysis;
Irinotecan
- MeSH:
Antineoplastic Agents, Phytogenic/therapeutic use;
Camptothecin/*analogs & derivatives/therapeutic use;
DNA Topoisomerases, Type I/antagonists & inhibitors;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Kidney Failure, Chronic/complications/*therapy;
Lung Neoplasms/complications/*drug therapy;
Male;
Middle Aged;
Renal Dialysis/*methods;
Small Cell Lung Carcinoma/complications/*drug therapy
- From:The Korean Journal of Internal Medicine
2009;24(1):73-75
- CountryRepublic of Korea
- Language:English
-
Abstract:
The prognosis of patients with end-stage renal disease has improved with advances in hemodialysis techniques. However, many patients who undergo hemodialysis suffer from various types of cancer. Limited data is available to guide clinical management of these patients who may have impaired renal function. Here, we report our experience with the use of irinotecan for the treatment of a hemodialysis patient with small-cell lung cancer and end-stage renal disease.
